Evdi is a drug owned by Apotex Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 18, 2043. Details of Evdi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12303506 | Trabectedin Composition |
Feb, 2043
(16 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Evdi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Evdi's family patents as well as insights into
ongoing legal events
on those patents.
Evdi's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Evdi:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS | M.D. Anderson Cancer Center | NA | RECRUITING
(Aug 1, 2026) | PHASE2 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | M.D. Anderson Cancer Center | NA | RECRUITING
(Aug 1, 2026) | PHASE1 |
| Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma | Centre Oscar Lambret | NA | COMPLETED
(Mar 1, 2026) | PHASE2 |
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma | Italian Sarcoma Group | NA | RECRUITING
(Mar 1, 2026) | PHASE2 |
| Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma | Italian Sarcoma Group | NA | RECRUITING
(Mar 1, 2026) | PHASE2 |
Generic Launch
Generic Release Date:
Evdi's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 18, 2043 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Evdi Generics:
There are no approved generic versions for Evdi as of now.
Alternative Brands for Evdi
There are several other brand drugs using the same active ingredient (Trabectedin) as Evdi. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Janssen Prods |
|
About Evdi
Evdi is a drug owned by Apotex Inc. Evdi uses Trabectedin as an active ingredient. Evdi was launched by Apotex in 2026.
Approval Date:
Evdi was approved by FDA for market use on 01 May, 2026.
Active Ingredient:
Evdi uses Trabectedin as the active ingredient. Check out other Drugs and Companies using Trabectedin ingredient
Dosage:
Evdi is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG/20ML (0.05MG/ML) | SOLUTION | Prescription | INTRAVENOUS |